Pharmacyte Biotech Inc (OTCMKTS:PMCB) released an educational article that will allow people to know about its technology and its application in pancreatic cancer treatment. It is the first release in a series of articles for making is technology known among public. These articles will be authored by oncologists, doctors and scientists who are associated with company’s upcoming Phase IIb clinical study. This first educational article is written by Pharmacyte’s CEO, Dr. Gerald W. Crabtree, with an objective of explaining the innovative treatment.
The CEO said that with so many articles, emails and telephone calls describing the treatment and technology for pancreatic cancer incorrectly, as a resident scientist and CEO of Pharmacyte, he felt it was important to assist the public and shareholders understand the technology and its application before they commence clinical trial in humans.
In last trading session, the stock price of Pharmacyte gained more than 1% to close the trading session at $0.0842.
Natural Alternatives International, Inc. (NASDAQ:NAII) Reports FY2015 Results
Natural Alternatives International, Inc. (NASDAQ:NAII) reported net income of $3.3 million on net sales of $79.5 million for the year completed June 30, 2015. The net sales from its contract manufacturing segment jumped 3.5% over the prior fiscal year due to higher sales volumes of currently selling products in existing markets along with new product sales to new clients.
CarnoSyn® beta-alanine licensing and royalty revenue jumped 67.9% to $9.1 million in FY2015 against $5.4 million for FY2014. The increase can be attributed to jump in raw material sales resulting from the direct distribution and sale of CarnoSyn® beta-alanine.
After recording strong gains in last few days, Uluru Inc (OTCMKTS:ULUR) recorded losses of 9.79% and 14.29% on Monday and Tuesday, respectively. On September 11, 2015, the company confirmed a definitive deal to sell nearly 4.079 million shares of its common stock to a group of European investors.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: